Clever-1 in cancer – Assessing the efficacy of a novel immunotherapy approach in patient derived explant cultures
Year: 2020
Type: dissertation
Abstract: The efficacy of oncological treatments has developed significantly in the past few decades but yet various types of cancer still lack curative treatment. In cancer immunotherapies the object is to guide one’s own immune system to detect and desolate the cancerous cells. This method allows reduced use of toxic chemotherapies in oncology. With the use of immunotherapies there have been unprecedented results in treated cancer patients on the depletion of tumor and metastasis. A form of active immunotherapy called immune checkpoint blockade (ICB) targets the key regulators of the immune system and induce inflammatory activation, aiming to re-establish inflammation in the site of the tumor. Targeting of immunosuppressive macrophages with anti-Clever-1 drug is a novel approach in immune-oncological treatments. Humanized anti-Clever-1 antibody is already in phase I/II clinical trials in cancer patients with selected metastatic or inoperable solid tumors and this study is aimed to help to understand the biological effect of this drug in cancer. With the use of breast cancer patient material that was acquired in collaboration with Turku university hospital we were able to study the expression of Clever-1+ macrophages and CD8+ T cells in the tumor microenvironment with use of immunohistochemistry. In addition, we conducted a novel assay where we co-cultured the patient tumor tissue with peripheral blood mononuclear cells (PBMCs) that are immune cells we extracted from the blood of the test subjects and treated them with anti-Clever-1 antibody. The idea of this assay was to image if the treated cells induce apoptosis in the tumor in relation to control samples. This unique assay made it possible for us to image the biological response of the tumor tissue more accurately than with the use of basic 2D cell cultures. The results show how these anti-Clever-1 treated PBMCs induce higher amounts of apoptosis in the tumor compared to the controls. This assay thus proved unprecedented results on anti-Clever-1 treatment’s biological effects in the tumor site and is a solid addition to previous studies on the subject. What is more, this novel explant assay is applicable to be used in further studies using different combinations of antibodies and in imaging their biological effects in the tissue, ex vivo.
Source: UTUPub (University of Turku)
Author: Arno Ylitalo
Institution: University of Turku
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W3012925857
